Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, has launched Oxtellar XR tablets in the US. Oxtellar XR is a novel once-daily extended release antiepileptic drug indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age.

The product has been shipped to major wholesalers in the market, and the company's sales force of approximately 75 sales representatives will start promoting the product on February 4.

"The commercial launch of Oxtellar XR marks the achievement of our vision of becoming a commercial organization marketing its own products in the CNS specialty pharma sector. It also confirms the long standing heritage we have in strong execution against our corporate goals said Jack Khattar, President & CEO, of Supernus. I would like to thank all Supernus employees for their hard work and dedication that allowed us to deliver on our commitment to providing innovative therapeutic options to patients who suffer from epilepsy," added Jack Khattar.

Supernus Pharmaceuticals, Inc. is focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.